头颈部鳞癌患者的肿瘤复发、第二原发及并发症导致肿瘤治疗失败,且各种治疗方法都有其自身的局限性。靶向治疗的应用,使肿瘤治疗方法的选择逐渐增多。表皮生长因子受体(EGFR)参与肿瘤的发生及发展,并与患者的不良预后有关,因此,第一个靶向治疗药物抗表皮生长因子受体的单克隆抗体西 Head and neck squamous cell carcinoma patients with tumor recurrence, the second primary and complications lead to the failure of tumor treatment, and various treatment methods have their own limitations. The application of targeted therapy, the selection of cancer treatment methods gradually increased. Epidermal growth factor receptor (EGFR) is involved in the occurrence and development of tumors and is associated with poor prognosis in patients. Therefore, the first monoclonal antibody against epidermal growth factor receptor